Drupal.behaviors.print = function(context) {window.print();window.close();}>
Isis Exec Sees Antisense as Third Major Drug Platform, Says More Work to Be Done
April 19, 2012
Isis Exec Sees Antisense as Third Major Drug Platform, Says More Work to Be Done
Full-text access for premium subscribers only.
Existing premium subscribers
login here
.
New to GenomeWeb?
Register here
quickly.
Related Stories
Isis Studies Suggest Therapeutic Potential of Single-Stranded RNAi Molecules
September 6, 2012 / Gene Silencing News
Snapshot: Partnership Goals, Track Records in the RNAi/miRNA Space
July 22, 2010 / Gene Silencing News
Choosing Skin and Eye Disorders, RXi Will Face Well-Worn R&D Paths
June 17, 2010 / Gene Silencing News
Key RNAi-Based Drugs in the Clinic
November 12, 2009 / Gene Silencing News
Santaris Advances Two Hypercholesterolemia Rx Candidates; One Poised to Enter Clinical Trials in 2010
November 5, 2009 / Gene Silencing News